There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .
A novel augmentation strategy for treating resistant major depression.
OBJECTIVE Treatment-resistant depression is a significant public health concern ; drug switching or augmentation often produce limited results . The authors hypothesized that fluoxetine could be augmented with olanzapine to successfully treat resistant depression . METHOD An 8-week double-blind study was conducted with 28 patients who were diagnosed with recurrent , nonbipolar , treatment-resistant depression without psychotic features . Subjects were r and omly assigned to one of three groups : olanzapine plus placebo , fluoxetine plus placebo , or olanzapine plus fluoxetine . RESULTS Fluoxetine monotherapy produced minimal improvement on various scales that rate severity of depression . The benefits of olanzapine monotherapy were modest . Olanzapine plus fluoxetine produced significantly greater improvement than either monotherapy on one measure and significantly greater improvement than olanzapine monotherapy on the other measures after 1 week . There were no significant differences between treatment groups on extrapyramidal measures nor significant adverse drug interactions . CONCLUSIONS Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone
There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .